Icosapent Ethyl
Colon Cancer Liver Metastasis
University of LeedsActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
33 Active assets in the Colon Cancer Liver Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Fudan University | Phase 4 | BBB |
Fruquintinib Peking University | Phase 3 | BBB |
DEXAMETHASONE Fudan University | Phase 3 | BB |
Capecitabine Jun Huang | Phase 3 | BB |
Irinotecan Jun Huang | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Icosapent Ethyl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →